Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: A randomized, double blind trial

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 4, 2001, Pages 1610-1615

  Bergh, Florian Then ^a   Kümpfel, Tania ^b   Grasser, Annette ^b   Rupprecht, Rainer ^b   Holsboer, Florian ^b   Trenkwalder, Claudia ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUOCORTOLONE; MOCLOBEMIDE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; MULTIPLE SCLEROSIS; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; RELAPSE;

EID: 0035030236     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.4.7416     Document Type: Article

References (43)

1. Biotechnological agents for the immunotherapy of multiple sclerosis: Principles, problems and perspectives
2. Mechanisms of glucocorticoid action on immune processes
3. Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates
4. Immune-neuro-endocrine interactions: Facts and hypotheses
5. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: Actions and mechanisms of action
6. Results of adrenal and pituitary stimulation tests in patients with multiple sclerosis
7. Serum cortisol levels of multiple sclerosis patients during ACTH treatment
8. ACTH-induced cortisol production in multiple sclerosis
9. Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function
10. Dexamethasone suppression test abnormalities in multiple sclerosis: Relation to ACTH therapy
11. Heterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosis
12. The neuroendocrine axis in patients with multiple sclerosis
13. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: Association with cerebral inflammation
14. Adrenal size is increased in multiple sclerosis
15. Increased activity of hypothalamic corticotropin-releasing hormone neurons in multiple sclerosis
16. Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis
17. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of multiple sclerosis
18. Animal models
19. Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids
20. The effects of the anti-glucocorticoid RU 38486 on steroid-mediated suppression of experimental allergic encephalomyelitis (EAE) in the Lewis rat
21. The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat
22. A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: Implications for treatment of inflammatory brain disease
23. Susceptibility and resistance to experimental allergic encephalomyelitis: Relationship with hypothalamic-pituitary-adrenal axis responsiveness in the rat
24. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia
25. The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: Laboratory and clinical studies
26. Cortisol response to a combined dexamethasone-human-cor ticotropin-releasing hormone challenge in patients with depression
27. The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders
28. Corticosteroid receptor function is decreased in depressed patients
29. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?
30. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects
31. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain
32. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system
33. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide
34. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
35. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
36. Development of a rating scale for primary depressive illness
37. Assessment of the hypothalamic-pituitary-adrenal axis function after corticosteroid therapy for MS relapses
38. Recovery of the hypothalamic-pituitary-adrenal axis from suppression by short-term, high-dose intravenous prednisolone therapy in patients with MS
39. Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test
40. Randomised trial of oral and intravenous methylprechrisolone in acute relapses of multiple sclerosis
41. Restoring production of hippocampal neurons in old age